off
Horizon Pharma raises bid for Depomed to $33 per share
Depomed said its Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the company and its shareholders.
Posted On Jul 22 2015
